AU2022347445A1 - Switch receptors using il-9 signaling domains - Google Patents

Switch receptors using il-9 signaling domains Download PDF

Info

Publication number
AU2022347445A1
AU2022347445A1 AU2022347445A AU2022347445A AU2022347445A1 AU 2022347445 A1 AU2022347445 A1 AU 2022347445A1 AU 2022347445 A AU2022347445 A AU 2022347445A AU 2022347445 A AU2022347445 A AU 2022347445A AU 2022347445 A1 AU2022347445 A1 AU 2022347445A1
Authority
AU
Australia
Prior art keywords
cell
nucleic acid
seq
cells
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022347445A
Other languages
English (en)
Inventor
John Connolly
Sean Parker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Institute for Cancer Immunotherapy
Original Assignee
Parker Inst For Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Inst For Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy filed Critical Parker Inst For Cancer Immunotherapy
Publication of AU2022347445A1 publication Critical patent/AU2022347445A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
AU2022347445A 2021-09-17 2022-09-16 Switch receptors using il-9 signaling domains Pending AU2022347445A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245661P 2021-09-17 2021-09-17
US63/245,661 2021-09-17
PCT/US2022/076612 WO2023044457A1 (en) 2021-09-17 2022-09-16 Switch receptors using il-9 signaling domains

Publications (1)

Publication Number Publication Date
AU2022347445A1 true AU2022347445A1 (en) 2024-04-04

Family

ID=83688655

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022347445A Pending AU2022347445A1 (en) 2021-09-17 2022-09-16 Switch receptors using il-9 signaling domains
AU2022348588A Pending AU2022348588A1 (en) 2021-09-17 2022-09-16 Switch receptors using il-9 signaling domains

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022348588A Pending AU2022348588A1 (en) 2021-09-17 2022-09-16 Switch receptors using il-9 signaling domains

Country Status (7)

Country Link
US (5) US12202884B2 (cg-RX-API-DMAC7.html)
EP (2) EP4402161A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024535868A (cg-RX-API-DMAC7.html)
CN (2) CN118251410A (cg-RX-API-DMAC7.html)
AU (2) AU2022347445A1 (cg-RX-API-DMAC7.html)
CA (2) CA3232664A1 (cg-RX-API-DMAC7.html)
WO (2) WO2023044457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12291651B2 (en) 2021-04-07 2025-05-06 Wisconsin Alumni Research Foundation Liquid crystal-infused slippery anti-fouling surfaces
CA3231615A1 (en) * 2021-09-17 2023-03-23 Mikko SIURALA Chimeric antigen receptors comprising interleukin-9 receptor signaling domain
EP4402161A1 (en) 2021-09-17 2024-07-24 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
WO2024019984A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cytokine receptor switch polypeptides and uses thereof
WO2025039159A1 (en) * 2023-08-21 2025-02-27 Hangzhou Hervor Therapeutics Co., Ltd Synthetic cytokine signaling system, preparation method, and uses thereof
WO2025117789A1 (en) * 2023-12-01 2025-06-05 Parker Institute For Cancer Immunotherapy Engineered immune signaling constructs
WO2026024685A1 (en) * 2024-07-23 2026-01-29 Feromics Inc. Uses of immunomodulatory fusion proteins to enhance efficacy of car-expressing immune effector cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
WO2010006111A2 (en) 2008-07-10 2010-01-14 Merck & Co., Inc. Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
MA41538A (fr) * 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
CA2974998C (en) 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
GB201514875D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Receptor
JP7299021B2 (ja) 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
AU2016374497B2 (en) 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
CN109880803B (zh) * 2017-12-06 2024-06-07 恺兴生命科技(上海)有限公司 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
AU2019227979B2 (en) 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
CN110615843B (zh) 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
JP2020110135A (ja) 2019-01-09 2020-07-27 エーテーハー チューリッヒEth Zurich 汎用細胞外分子センサー
JP2022519704A (ja) 2019-02-08 2022-03-24 シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) キメラサイトカイン受容体
GB201911187D0 (en) * 2019-08-05 2019-09-18 Autolus Ltd Receptor
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
WO2021141986A1 (en) 2020-01-07 2021-07-15 St. Jude Children's Research Hospital, Inc. Chimeric gmcsf-il18 receptor
US20230138428A1 (en) * 2020-02-25 2023-05-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
JP2023520572A (ja) 2020-04-06 2023-05-17 シンセカイン インコーポレイテッド オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞
EP4305054A4 (en) 2021-03-09 2025-03-19 The Trustees of The University of Pennsylvania SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL ADMINISTRATION OF ORTHOGONAL IL-2
EP4082429A1 (en) * 2021-04-28 2022-11-02 Koninklijke Philips N.V. A shell cuff
US11688614B2 (en) * 2021-04-28 2023-06-27 Kla Corporation Mitigating thermal expansion mismatch in temperature probe construction apparatus and method
CA3231615A1 (en) 2021-09-17 2023-03-23 Mikko SIURALA Chimeric antigen receptors comprising interleukin-9 receptor signaling domain
EP4402161A1 (en) 2021-09-17 2024-07-24 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
EP4554972A1 (en) 2022-07-11 2025-05-21 The Board of Trustees of the Leland Stanford Junior University Tunable cytokine receptor signaling domains

Also Published As

Publication number Publication date
CA3232664A1 (en) 2023-03-23
WO2023044461A3 (en) 2023-05-11
JP2024535868A (ja) 2024-10-02
WO2023044457A1 (en) 2023-03-23
CN118251410A (zh) 2024-06-25
US12221469B2 (en) 2025-02-11
US20230110313A1 (en) 2023-04-13
US20230303661A1 (en) 2023-09-28
EP4402161A1 (en) 2024-07-24
WO2023044461A2 (en) 2023-03-23
US20250136664A1 (en) 2025-05-01
US20230265163A1 (en) 2023-08-24
CA3232668A1 (en) 2023-03-23
JP2024535872A (ja) 2024-10-02
EP4402162A2 (en) 2024-07-24
US12202884B2 (en) 2025-01-21
AU2022348588A1 (en) 2024-04-04
US20250179148A1 (en) 2025-06-05
CN118234746A (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
US12221469B2 (en) Switch receptors using IL-9 signaling domains
Lesch et al. T cells armed with CXC chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
JP2021176321A (ja) 養子細胞療法用の操作された細胞
JP2022190153A (ja) キメラサイトカイン受容体
JP2021516996A (ja) 生物学的に関連する直交サイトカイン/受容体対
JP2020195393A (ja) 養子細胞療法用の操作された細胞
US20170313759A1 (en) Novel chimeric antigen receptors
JP2020529841A (ja) ヒトドメインを有する抗b細胞成熟抗原キメラ抗原受容体
JP2019532625A (ja) 融合タンパク質を用いてt細胞受容体をリプログラミングするための組成物及び方法
JP2020537503A (ja) 抗cd19免疫療法によりがんを処置するための組成物および方法
Wang et al. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma
CN110709416A (zh) TGF-β诱饵受体
WO2022098750A1 (en) Hla class ii-restricted tcrs against the kras g12>v activating mutation
JP2025522459A (ja) Kras g12v突然変異ポリペプチドを標的するt細胞受容体及びその用途
KR20260070126A (ko) Car t 세포의 기능성을 향상시키기 위한 il-2 변이체를 함유하는 car-인게이저
Awad et al. In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4+ T cells
Zhang et al. Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles
KR20260033032A (ko) 합성 시토카인 수용체
AU2018308982A1 (en) Methods and compositions for the treatment of cancer
HK40109632A (en) Switch receptors using il-9 signaling domains
US20240352088A1 (en) Chimeric cytokine receptor
US20230226109A1 (en) Method for differentiating innate lymphoid cells for immunotherapy
TW202506711A (zh) 切換受體
TW202346576A (zh) 治療性t細胞產品
WO2024215989A1 (en) ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS